Ublituximab Reduces Thalamic Volume Loss and New Lesion Formation in Participants of the ULTIMATE I & II Phase 3 Studies

site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
Drug Category : Array
Conference Category : Array
Lead Author : Arnold D, et al.
Published Date : 11/10/2023
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2023/10/Arnold-Thalamic-Volume_ECTRIMS-2023_Poster-Draft_Final.pdf
Download Text : Download
Popup Confirmation? :
astra-migrate-meta-layouts : set
Scroll to Top